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RESULTS: Healthcare utilization and concomitant costs
(denominated in the Euro) for naive type 2 diabetic patients
initiated on Diamicron varied greatly between these prac-
tices in the UK and France. The biggest difference in utiliza-
tion was greater use in France of hospital inpatient and hos-
pital outpatient services. Total annual direct medical costs
in France were approximately 1,620 Euro (10,600FF), com-
pared with 454 Euro (320 BP) in the UK. Costs of Diami-
cron, as actually prescribed and used by the patients, also
varied considerably: 112 Euro in France versus 65 Euro in
the UK.
CONCLUSION: Patient care and associated costs for pa-
tients newly diagnosed with a common clinical condition
such as diabetes can vary considerably even within popu-
lous western European nations. Analyses of cost of illness
and cost effectiveness must be careful to use country-spe-
cific data in order to maximize the utility of these analyses
by relevant decision-makers within those countries.
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OBJECTIVE: To offer direct cost estimates of patients with
diabetes mellitus based on retrospectively collected data.
METHODS: A multicenter, retrospective observational
study on 30 diabetic centres located in 12 different re-
gions of Italy. Each diabetes centre randomly selected be-
tween 60 and 100 patients with diabetes mellitus. A total
of 2,135 patients were enrolled. For each patient data on
resource consumption was collected retrospectively—on
the two months preceding the enrolment—using a ques-
tionnaire filled in by physicians of the participant centres.
Per patient-year direct cost estimates were produced, tak-
ing the Italian National Health Service (INHS) perspec-
tive, by linking per patient service use data with INHS
tariffs of day-hospital admissions, outpatient visits, labo-
ratory and diagnostic tests, and drug prices. Drug cost
was calculated by multiplying the daily dose by the pub-
lic price when taken at home, and by 50% of the public
price when taken in hospital and ambulatory setting.
RESULTS: Total direct medical cost per patient was on av-
erage Italian L. 1,708,364 for Type I diabetes (N  572;
mean age 51.7) and L. 1,623,728 for Type II diabetes (N 
1,563; mean age 61.4). Drugs accounted for 32% of the
total cost in Type I patients and 17% in Type II, while out-
patient care, day-hospital admissions included, accounted
for 68% and 83%. Inpatient costs were not included.
CONCLUSION: This study suffers some major limits. Only
patients, and not centres, were randomly selected; resource
use data was retrospectively collected over two months of
observations, and unit costs were based on INHS tariffs.
However, since in Italy the cost of diabetes has received lim-
ited attention, we believe this study presents some interest-
ing information on the burden of diabetes in this country.
PEN8
CODE-2* UK: THE CURRENT COSTS OF TYPE-2 
DIABETES IN THE UK
Bottomley J1, Baxter H2, Lawlor D2, Williams W2, Burns E3, 
Young R3, Harvey J4, Sheaves R4, Sheldon P5
1SmithKline Beecham Pharmaceuticals, Welwyn Garden City, 
UK; 2Nuffield Institute, Leeds, UK; 3Hope Hospital, Salford, UK; 
4Health and Social Services, St Helier, Jersey, Channel Islands, 
UK; 5Bradford Health Authority, West Yorkshire, UK
OBJECTIVES: As part of a pan-European cost of illness
study in eight countries (CODE-2*: Costs of Diabetes in
Europe, Type 2) the CODE-2* UK objective was to mea-
sure cost of care for patients with type 2 diabetes (T2D) in
terms of management and complication costs in the UK.
METHODS: This was a bottom-up, prevalence-based
study design, which collected resource use and clinical out-
come data across primary and secondary care. Data
sources include comprehensive population-based diabetes
registers (the ‘primary databases’) and hospital and pri-
mary care records (‘secondary databases’). 756 T2D pa-
tients (defined as aged 30 or above at diagnosis) were iden-
tified from 3 registers. Clinical data was reviewed against
treatment guidelines to assess status of T2D management.
Preliminary results based on data in the 6-month period
July 1st to December 31st 1998 were analyzed first.
RESULTS: Assuming a UK prevalence of T2D of 2% the
total direct medical costs for people with T2D in the UK in
1998 were estimated to be £1.83 billion or 3.4% of health-
care expenditure. Average costs for patients with T2D were
£1550 per year. The costs attributed to oral anti-diabetic
drugs comprised 2.7% of overall direct costs. Costs for pa-
tients with T2D with microvascular and macrovascular
complications with indicators of Insulin Resistance Syn-
drome were higher than for patients without complica-
tions. The proportion of patients achieving good glycemic
control (6.5% HBA1c) decreased as patients progressed
from diet and exercise through to insulin alone or in com-
bination, highlighting the progressively increasing need for
treatment as duration of disease increases.
CONCLUSIONS: CODE-2* UK provides evidence of di-
rect costs and management of T2D in the NHS. It is a rich
data set to inform Health Boards, Health Authorities and
Primary Care Groups of how costs are composed and the
likely outcomes seen for T2D management. *Trademark
of SmithKline Beecham plc.
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ABSTRACT OBJECTIVE: To develop a pharmacody-
namic-pharmacoeconomic model to compare effectiveness
and costs of anti-inflammatory therapies used in asthma
treatment.
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PARTICIPANTS WHO WOULD BENEFIT: Members
of P&T, MCO and others assessing formulary inclusion
and cost-benefits of asthma therapies. Asthma has in-
creased 10-fold in the last 2 decades, costing $6 B/year in
the US. The most severe asthmatics account for the majority
of the total health care costs, endpoints involving emergency
department treatment ($250) and hospital admission
($3100). Anti-inflammatories (steroids, leukotriene modifi-
ers) are recommended for most levels of asthma severity and
should be able to alter these endpoints. However, initial pre-
scription filling (50–80%) and refilling (20–40%) rates are
so poor as to preclude comparisons of drug effectiveness
or health care plans. While disease management of asthma
would wish to alter these endpoint costs, it is not possible
to develop a PD-PE model to compare effectiveness of
asthma anti-inflammatories across or within plans.
OBJECTIVES: To develop a PD-PE model to compare ef-
fectiveness of anti-inflammatory therapies. To obviate the
above limitations, we used published clinical results in-
volving moderate-severe asthmatics in terms of improved
lung function ((0.1L FEV1) calibrated against the anti-
inflammatory inhaled therapy costs (per-day  treatment
duration). Additional cost reductions related to reduced
need for metered dose inhalers were also tabulated.
RESULTS: These analyses show $US costs to achieve a
0.1L improvement in moderate-severe asthmatics using
steroids such as budesonide ($232) or beclomethasone
($110), leukotriene modifiers (zileuton $68 or montelukast
$101), as well as the single isomer -agonist levalbuterol
($39). Chronic treatment with racemic albuterol did not
improve lung function but rather resulted in a decrease in
lung function. Each final cost is inclusive of reduced al-
buterol metered dose inhaler costs.
CONCLUSIONS: This cross-stratified PD-PE model as-
sessed anti-inflammatory therapy impact on improvements
in asthma lung function and reduced need for rescue MDI.
As these results are derived from well-controlled clinical
studies, they reflect optimized treatment compliance and
therefore maximal PD-PE effect. Accordingly, these rela-
tive scores may provide insights relating to formulary in-
clusion of drugs which face class competition.
ECONOMIC AND OUTCOMES ISSUES OF 
GASTROINTESTINAL DISORDERS
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EFFECTIVENESS OF OMEPRAZOLE, 
AMOXICILLIN, AND CLARITHROMYCIN IN 
ERADICATING HELICOBACTER PYLORI IN 
PATIENTS ON CHRONIC ACID SUPPRESSION 
FOR PEPTIC ULCER DISEASE OR
ULCER-LIKE SYMPTOMS
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Libran D
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OBJECTIVE: To evaluate the effectiveness of the omepra-
zole, amoxicillin, and clarithromycin (OAC) regimen in
eradicating H. pylori (HP) in patients on long term acid
suppression medicine for documented ulcer or ulcer like
symptoms.
METHODS: Kaiser Permanente data bases were accessed
to identify all patients receiving acid suppression therapy
for at least three 30-day periods within the most recent 12-
month time frame. Those identified were then matched to
databases that capture physician recorded diagnoses at
each patient visit. Patients not previously treated for HP
and with documented (by endoscopy or UGI) diagnoses of
duodenal ulcer (DU), gastric ulcer (GU), gastritis, and un-
specified peptic ulcer disease (PUD) or ulcer like symptoms
were selected for recruitment. Study participants were ran-
domly assigned to C14 urea breath testing (UBT) and HP
eradication, if positive, versus standard maintenance acid
suppressive therapy. All patients positive on UBT (except
those allergic to penicillin N  12) were treated with ome-
prazole 20 mg, amoxicillin 1gm, clarithromycin 500 mg
bid for 10 days. Proof of eradication was documented by
UBT administered 4 weeks post treatment. Each patient
testing negative after treatment was taken off acid reduc-
ing medication and followed for up to one year.
RESULTS: Ninety-five of 96 patients completed 10 days
of OAC, and 89 have been retested 4 weeks later. Of those
retested, 85% (95% CI  76%, 92%) were breath test
negative and 15% (95% CI  8%, 24%) were breath test
positive. Fourteen participants reported recurrent symp-
toms following HP eradication. Side effects of patients on
the regimen were reported by 6 out of 96 treated (6%),
and included bloody diarrhea (1), rash (4), and abdominal
cramps (2).
CONCLUSION: OAC is an effective regimen for eradicat-
ing HP in infected patients on chronic acid suppression for
PUD or ulcer like symptoms. Compliance with the regi-
men is high and serious adverse reactions are low.
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PURPOSE: To assess the cost of care associated with the
treatment of constipation subjects.
METHODS: All subjects contained within PharMetrics In-
tegrated Outcomes database possessing an ICD-9-CM 
564.0 between January 1, 1996 and March 31, 1998 were
eligible for study inclusion. Subjects were required to have
data available for analysis 6 months preceding and follow-
ing the date of their constipation diagnosis. Charge data
were evaluated over the 6-month intervals surrounding the
index date. Additionally, monthly charges were plotted
over the entire 12-month interval to allow examination of
trends associated with the diagnosis and treatment of con-
